Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder
Status:
Terminated
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, parallel-group, multi-site, Phase 3, placebo
controlled fixed-dose study of PD 0332334 and paroxetine in 528 outpatients with generalized
anxiety disorder. Subjects will be randomized to the following treatments (132 subjects per
treatment group):
PD 0332334 225 mg twice a day (450 mg/day), PD 0332334 300 mg twice a day (600 mg/day),
placebo once a day in the morning or paroxetine 20 mg once a day in the morning (20 mg/day).